PfizerPFE
Daily Market Briefing
Latest briefing
Pfizer's TUKYSA regimen approved for front-line HER2+ breast cancer maintenance
Pfizer's TUKYSA regimen, in combination with trastuzumab and pertuzumab, has been approved by the FDA as a front-line maintenance treatment for HER2-positive metastatic breast cancer. This approval offers a new chemotherapy-free maintenance option, potentially improving progression-free survival for patients.
Previous briefings
Pfizer's TUKYSA regimen approved for HER2+ breast cancer maintenance treatment.
Pfizer's TUKYSA regimen, combined with trastuzumab and pertuzumab, has been approved by the FDA as a front-line maintenance treatment for adults with HER2-positive metastatic breast cancer. This approval is based on the Phase 3 HER2CLIMB-05 trial, which demonstrated a 35.9% reduction in the risk of disease progression or death compared to placebo. Additionally, Pfizer will present 57 abstracts at IDWeek 2026, showcasing advancements in infectious disease research, including data on pneumococcal vaccines and RSV treatments.
Pfizer's TUKYSA regimen approved for front-line HER2+ breast cancer maintenance
Pfizer's TUKYSA® (tucatinib) regimen, in combination with trastuzumab and pertuzumab, has been approved by the U.S. Food and Drug Administration (FDA) as a front-line maintenance treatment for adults with unresectable locally advanced or metastatic HER2-positive breast cancer. This approval offers a new chemotherapy-free maintenance option that may help further delay disease progression.
Pfizer's stock price rises to $28.40 amid job cuts and analyst upgrades
Pfizer's stock price increased to $28.40 following recent developments, including the announcement of job cuts in Italy and analyst upgrades. The company plans to reduce approximately 330 positions at its Sicily plant, a move that aligns with its ongoing cost optimization efforts. Additionally, Scotiabank raised Pfizer's price target to $33 from $30, maintaining an Outperform rating, citing the company's strong pipeline and strategic initiatives.
Pfizer's stock rises 1.6% after JPMorgan raises price target to $30.
Pfizer's stock experienced a 1.6% increase following JPMorgan's decision to raise its price target from $28 to $30, maintaining a neutral rating. This adjustment reflects confidence in Pfizer's strategic initiatives and recent developments.
Pfizer's LITFULO shows significant repigmentation in vitiligo patients.
Pfizer's LITFULO (ritlecitinib) demonstrated significant improvement in facial and total body repigmentation in patients with nonsegmental vitiligo, according to results from two Phase 3 trials. This positive outcome may enhance the company's position in dermatology.
Pfizer's TUKYSA approved for front-line HER2+ breast cancer treatment.
Pfizer's TUKYSA regimen has received FDA approval as a front-line maintenance treatment for HER2-positive metastatic breast cancer, potentially expanding its market reach. Additionally, the company declared a fourth-quarter 2026 dividend of $0.43 per share, reflecting confidence in its financial position.
Pfizer's TUKYSA regimen approved for front-line HER2+ breast cancer maintenance
Pfizer's TUKYSA regimen has received FDA approval as a front-line maintenance treatment for HER2-positive metastatic breast cancer, potentially expanding its market reach. Additionally, the company declared a $0.43 per share dividend for Q4 2026, marking its 352nd consecutive quarterly dividend.
Pfizer's TUKYSA regimen approved for front-line HER2+ breast cancer treatment
Pfizer's TUKYSA regimen has received FDA approval as a front-line maintenance treatment for HER2-positive metastatic breast cancer. This approval is expected to enhance Pfizer's oncology portfolio and potentially boost revenue from cancer therapies.
Pfizer declares $0.43 dividend; Scotiabank raises price target to $33
Pfizer's stock is experiencing positive momentum following the declaration of a $0.43 per share dividend for Q4 2026 and an increased price target from Scotiabank. These developments reflect investor confidence in Pfizer's financial health and growth prospects.
Pfizer stock declines 1.4% amid competitor's positive vaccine trial results
Pfizer's stock fell 1.4% to $27.41 on October 5, 2026, following Vaxcyte's announcement of positive results for a competing vaccine candidate. This development raises concerns about Pfizer's market share in the $3 billion to $6 billion vaccine market.
Pfizer's eczema drug shows 61% response rate amid Florida lawsuit
Pfizer's eczema treatment achieved a 61% response rate in recent trials, coinciding with a lawsuit filed by Florida alleging deceptive marketing practices. The stock closed at $27.81 on October 2, 2026, down 1.11% from the previous day.
Pfizer stock declines 1.14% to $27.80 amid revenue guidance increase
Pfizer's stock experienced a 1.14% decline to $27.80 on October 2, 2026, following the company's announcement of a $500 million increase in its full-year 2026 revenue guidance. Despite the guidance raise, the stock remains below its 52-week high of $29.21, indicating investor caution.
Pfizer's eczema drug LITFULO shows significant skin clearance in Phase 3 trials.
Pfizer's eczema treatment, LITFULO (ritlecitinib), has demonstrated significant skin clearance in Phase 3 trials, potentially enhancing its market position. Additionally, the company is advancing its oncology portfolio, with several key pivotal readouts expected over the next 12 months. These developments may positively influence investor sentiment and stock performance.
Pfizer's eczema drug shows significant skin clearance in Phase 2 study.
Pfizer's eczema treatment, tilrekimig (PF-07275315), demonstrated significant skin clearance in a Phase 2 study for adults with moderate-to-severe atopic dermatitis. This promising result could enhance Pfizer's dermatology portfolio and market position.
Pfizer stock closes at $28.72, up 0.09% after-hours; ESMO oncology program announced.
Pfizer's stock experienced a slight after-hours increase following the announcement of its participation in the European Society for Medical Oncology (ESMO) Congress. The company plans to present data from 45 research abstracts at the event in Madrid from October 23 to 27, 2026. Additionally, Pfizer has scheduled its third-quarter 2026 earnings report for November 3, 2026.
Pfizer's stock rises 1.7% to $29 after Q2 earnings beat and Depo-Provera settlement.
Pfizer's stock price increased by 1.7% to $29 following the release of its second-quarter 2026 earnings, which exceeded analyst expectations. Additionally, the company reached a confidential settlement covering over 6,000 federal Depo-Provera lawsuits, potentially reducing legal uncertainties.
Envestnet Asset Management Inc. increases Pfizer stake by 1.8%, now holding 9.51M shares.
Envestnet Asset Management Inc. has raised its holdings in Pfizer Inc. by 1.8%, acquiring an additional 167,641 shares, bringing its total to 9.51 million shares valued at approximately $229.1 million. This move reflects continued institutional confidence in Pfizer's financial performance and strategic direction.
Pfizer's stock rises 0.95% to $28.67 amid positive analyst outlook.
Pfizer's stock price increased by 0.95% to $28.67, reflecting positive investor sentiment. Analysts highlight the company's strong pipeline and cost-cutting initiatives as key growth drivers. Additionally, Envestnet Asset Management Inc. raised its stake in Pfizer by 1.8%, indicating confidence in the company's prospects.
Pfizer's stock price rises to $28.18 amid positive Q2 earnings and FDA approval.
Pfizer's stock price increased to $28.18 following the release of its second-quarter 2026 earnings report, which showed a 3% year-over-year revenue growth to $15.0 billion. Additionally, the U.S. Food and Drug Administration approved Pfizer and BioNTech's updated COVID-19 vaccine for the 2026-2027 season, potentially boosting future revenues.
Pfizer's stock declines 1.4% to $27.66 amid investor concerns over revenue and dividends.
In the past 24 hours, Pfizer's stock price fell by 1.4% to $27.66, reflecting investor concerns over declining post-pandemic revenue and the sustainability of its dividend yield. Analysts maintain a consensus 'Hold' rating with an average price target of $28.28.
Pfizer's stock rises 1.6% to $27.30 amid positive vaccine news and pipeline progress.
Pfizer's stock price increased by 1.6% to $27.30, driven by the European Medicines Agency's validation of its Lyme disease vaccine application and advancements in its obesity drug pipeline. The broader healthcare sector's strength also contributed to the positive momentum.
Pfizer stock holds steady at $27.72 amid FDA approval of updated COVID-19 vaccine
Pfizer's stock price remained stable at $27.72 following the FDA's approval of its updated COVID-19 vaccine for the 2026-2027 season. The vaccine targets the XFG variant, with shipments beginning immediately. Analysts maintain a consensus "Hold" rating with an average price target of $28.28.
Pfizer's stock drops 5.39% to $4,348.70 amid broader market declines.
Pfizer's stock experienced a significant decline of 5.39%, closing at $4,348.70, as part of a broader market downturn. This downturn affected several major stocks, including NIACL and IFCI, which also saw steep declines. The market-wide sell-off was driven by various factors, including investor concerns over economic indicators and global market trends.
Pfizer's stock declines 1.25% to $28.45 amid profit-taking and valuation concerns.
Pfizer's stock experienced a 1.25% decline to $28.45, attributed to profit-taking and valuation concerns. Despite recent positive developments, such as FDA approval for the 2026–2027 COMIRNATY XFG COVID-19 vaccine formulation, the stock's recent rally toward a 52-week high led to a pullback.
Pfizer's stock hits new 52-week high at $29.09 amid positive developments
Pfizer's stock reached a new 52-week high of $29.09, driven by a combination of positive factors. The company secured a favorable drug pricing agreement with the U.S. administration, reported stronger-than-expected second-quarter earnings, and resolved a significant legal settlement concerning one of its contraceptive products.
Pfizer's stock hits new 52-week high amid positive developments
Pfizer's stock reached a new 52-week high of $29.09 on September 1, 2026, driven by a confidential settlement in the Depo-Provera litigation and positive analyst sentiment. The company also reported strong earnings and raised its 2026 revenue outlook, further bolstering investor confidence.
Pfizer's Lyme disease vaccine application validated by EMA; stock up 1.6%
Pfizer's stock rose 1.6% following the European Medicines Agency's validation of its Lyme disease vaccine application. This development is expected to bolster the company's vaccine portfolio and revenue streams.
Pfizer's stock stabilizes at $27.95 after FDA approves new COVID-19 vaccine.
Pfizer's stock remains steady following the FDA's approval of its updated COVID-19 vaccine for the 2026/27 season. The vaccine is authorized for seniors and high-risk individuals, with shipments to U.S. pharmacies, hospitals, and clinics beginning immediately. However, the FDA has revoked the emergency use authorization for Pfizer's COVID-19 vaccine in children under five years old.
Pfizer's stock remains steady at $27.96 as FDA approves updated COVID-19 vaccine.
Pfizer's stock price has remained steady at $27.96 following the FDA's approval of its updated COVID-19 vaccine for the 2026-27 season. Analysts maintain a 'Hold' rating with a price target of $28.28, indicating cautious sentiment despite the vaccine approval.
Analyze any chart in seconds
This is today's read on Pfizer. Point your camera at any chart and ChartDetector AI gives you a full technical analysis in seconds — free on iPhone and Android.
AI-generated from public news sources. Not financial advice.
